Patents by Inventor Kuber T. Sampath

Kuber T. Sampath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220195025
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicants: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20220135664
    Abstract: The present invention relates to a pharmaceutical composition comprising an antibody that binds to BMP1.3 non-catalytic domain that contains either CUB-3 or CUB-4 or both CUB-3 and CUB-4 or EGF-2 or both CUB-3 and CUB-4 and EGF-2 and at the C-terminal region for use in prevention and/or therapeutic treatment of muscular dystrophy.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 5, 2022
    Inventors: Slobodan Vukicevic, Kuber T. Sampath
  • Publication number: 20220023494
    Abstract: An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof in a range of from 2 to 1000 ?g per ml of autologous blood; and hydroxyapatite, tri-calcium phosphate, or a mixture thereof as a compression resistant matrix, the compression resistant matrix being provided in the form of particles having a particle size in a range of from above 74 to 8000 ?m. Preferably, a ratio between the compression resistant matrix and the autologous blood coagulum is from 50 to 500 mg of the compression resistant matrix per mL of the autologous blood coagulum.
    Type: Application
    Filed: June 29, 2021
    Publication date: January 27, 2022
    Inventors: Slobodan Vukicevic, Kuber T. Sampath
  • Patent number: 11230595
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 25, 2022
    Assignees: Genzyme Corporation, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20210213165
    Abstract: An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects, a method of preparation thereof, and a method of inducing or promoting bone growth by treatment of a bone with an autologous bone graft substitute composition. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof; and a compression resistant matrix selected from the group consisting of a bone autograft, bone allograft, hydroxyapatite, tri-calcium phosphate, and combinations thereof. The autologous blood forms a coagulum gel comprising a fibrin-meshwork reinforced with the compression resistant matrix and containing the osteogenic bone morphogenetic protein which is released over a sustained period.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 15, 2021
    Inventors: Slobodan Vukicevic, Kuber T. Sampath, Lovorka Grgurevic, Charles Cohen, Hermann Oppermann
  • Patent number: 10960109
    Abstract: The present invention relates to an Autologous Bone Graft Substitute composition (ABGS) for inducing new bone formation, promoting bone growth and treating of bone defect, a preparation method of the Autologous Bone Graft Substitute composition, and a kit for preparing the Autologous Bone Graft Substitute composition of implant. In a particular aspect, the invention relates to an injectable/extrudable/implantable Autologous Bone Graft Substitute composition for use in treatment of bone defects, inducing new bone formation and promoting bone growth for bone fracture healing, spinal fusions and to repair bone defects in bone reconstructive procedures of orthopedic and oral maxillofacial-dental surgeries.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: March 30, 2021
    Assignee: Perform Biologies, Inc.
    Inventors: Slobodan Vukicevic, Kuber T. Sampath, Lovorka Grgurevic, Charles Cohen, Hermann Oppermann
  • Publication number: 20200237959
    Abstract: The present invention relates to an Autologous Bone Graft Substitute composition (ABGS) for inducing new bone formation, promoting bone growth and treating of bone defect, a preparation method of the Autologous Bone Graft Substitute composition, and a kit for preparing the Autologous Bone Graft Substitute composition of implant. In a particular aspect, the invention relates to an injectable/extrudable/implantable Autologous Bone Graft Substitute composition for use in treatment of bone defects, inducing new bone formation and promoting bone growth for bone fracture healing, spinal fusions and to repair bone defects in bone reconstructive procedures of orthopedic and oral maxillofacial-dental surgeries.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 30, 2020
    Inventors: Slobodan Vukicevic, Kuber T. Sampath, Lovorka Grgurevic, Charles Cohen, Hermann Oppermann
  • Publication number: 20190389943
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: July 1, 2019
    Publication date: December 26, 2019
    Applicants: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: 10377819
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 13, 2019
    Assignees: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20180104180
    Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminolycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.
    Type: Application
    Filed: May 23, 2017
    Publication date: April 19, 2018
    Inventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
  • Publication number: 20170247439
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: February 8, 2017
    Publication date: August 31, 2017
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: 9598486
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: March 21, 2017
    Assignees: GENZYME CORPORATION, BAYLOR COLLEGE OF MEDICINE
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20160031979
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: March 20, 2014
    Publication date: February 4, 2016
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20140271471
    Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminoglycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Genzyme Corporation
    Inventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
  • Patent number: 8748378
    Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: June 10, 2014
    Assignee: Stryker Corporation
    Inventors: Charles M. Cohen, Kuber T. Sampath, Slobodan Vukicevic
  • Patent number: 8673853
    Abstract: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: March 18, 2014
    Assignee: Stryker Corporation
    Inventors: Slobodan Vukicevic, Vladimir Katic, Kuber T. Sampath
  • Patent number: 8377878
    Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: February 19, 2013
    Assignee: Stryker Corporation
    Inventors: Kuber T. Sampath, Charles M. Cohen, Slobodan Vukicevic
  • Patent number: 8354375
    Abstract: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: January 15, 2013
    Assignee: Stryker Corporation
    Inventors: Slobodan Vukicevic, Vladimir Katic, Kuber T. Sampath
  • Publication number: 20120004171
    Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-? superfamily of proteins.
    Type: Application
    Filed: August 11, 2011
    Publication date: January 5, 2012
    Applicant: STRYKER CORPORATION
    Inventors: Kuber T. Sampath, Charles M. Cohen, Slobodan Vukicevic
  • Patent number: RE42954
    Abstract: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: November 22, 2011
    Assignee: Stryker Corporation
    Inventors: Slobodan Vukicevic, Vladimir Katic, Kuber T. Sampath